Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Balanced Hormone Health vs Medro

Balanced Hormone Health
Graded #388

Lower grade

vs+5.800000000000004
Medro
Graded #252

Higher grade

The verdict

Medro takes it — 63.6/100 to 57.8/100.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +5
45
50
Dose & formulationMedro +24
53
77
Clinical oversightBalanced Hormone Health +9
80
71
Labs & monitoringBalanced Hormone Health +2
54
52
FulfillmentMedro +30
62
92
Contract termsBalanced Hormone Health +22
55
33
Balanced Hormone Health · left barMedro · right bar

The numbers

MetricBalanced Hormone HealthMedro
WeighScore57.8/10063.6/100
GradeCC
Scorecard rank#388#252
SemaglutideNot disclosed$199/mo (compounded)
TirzepatideNot disclosed$299/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Balanced Hormone Health

Graded #388 · C

Strengths

  • Offers compounded semaglutide and tirzepatide plus GLP-1/GIP combo plans
  • Also lists a branded Zepbound prescription option
  • Rooted in hormone health (HRT/BHRT) for a whole-metabolic approach
  • Compounded formulas often paired with B vitamins
  • Provides receipts for HSA/HRA reimbursement

Where it loses points

  • Private-pay only; does not bill insurance
  • Compounded GLP-1 is not an FDA-approved finished drug
  • Some states excluded depending on the compounding pharmacy used
  • No transparent public monthly pricing readily listed
  • Pharmacy manufacturing adds roughly a week before shipment
Medro

Graded #252 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard